Enliven Therapeutics Chief Medical Officer Helen Louise Collins reports sale of $234,203.1101 in common shares
ELVN•Chief Medical Officer Helen Louise Collins sold 5,000 Enliven Therapeutics common shares on November 17, 2026, and exercised options for 5,000 shares at $2.48 each.




